TR201902400T4 - Multivalan antijen bağlama Fv molekülü. - Google Patents
Multivalan antijen bağlama Fv molekülü. Download PDFInfo
- Publication number
- TR201902400T4 TR201902400T4 TR2019/02400T TR201902400T TR201902400T4 TR 201902400 T4 TR201902400 T4 TR 201902400T4 TR 2019/02400 T TR2019/02400 T TR 2019/02400T TR 201902400 T TR201902400 T TR 201902400T TR 201902400 T4 TR201902400 T4 TR 201902400T4
- Authority
- TR
- Turkey
- Prior art keywords
- binding molecule
- antigen
- molecule
- antigen binding
- polypeptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Bir açıda, mevcut buluş iki polipeptit zincir içeren albumin ve CD3 için spesifik bir antijen bağlama molekülü ile ilgilidir, her bir polipeptit zincir, Fv oluşumunu önleyen bir oryantasyonda en az dört değişken alan içerir ve iki polipeptit zincir birbiri ile dimerize edilir, bu şekilde bir multivalan antijen bağlama molekülü oluşturulur. İki polipeptit zincirin her biri üzerinde, dört değişken alan polipeptitin N-terminalinden C-terminaline V L A-V H B-V L B-V H A sırasında düzenlenir. Antijen bağlama molekülümüm bileşimleri ve çeşitli hastalıkların tedavisine yönelik antijen bağlama molekülünün ve bunun bileşimlerinin kullanılmasına yönelik yöntemler burada sağlanır.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30820510P | 2010-02-25 | 2010-02-25 | |
EP10154751.1A EP2361936B1 (en) | 2010-02-25 | 2010-02-25 | Antigen-binding molecule and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201902400T4 true TR201902400T4 (tr) | 2019-03-21 |
Family
ID=42232726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/02400T TR201902400T4 (tr) | 2010-02-25 | 2011-02-25 | Multivalan antijen bağlama Fv molekülü. |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP2361936B1 (tr) |
DK (1) | DK2371866T3 (tr) |
ES (2) | ES2582001T3 (tr) |
HR (1) | HRP20190288T1 (tr) |
HU (1) | HUE041615T2 (tr) |
LT (2) | LT2361936T (tr) |
PL (2) | PL2361936T3 (tr) |
PT (2) | PT2361936T (tr) |
RS (1) | RS58352B1 (tr) |
SI (1) | SI2371866T1 (tr) |
TR (1) | TR201902400T4 (tr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2842649C (en) * | 2011-07-22 | 2020-01-21 | Affimed Therapeutics Ag | Multivalent antigen-binding fv molecule |
HUE045859T2 (hu) * | 2013-03-15 | 2020-01-28 | Amgen Res Munich Gmbh | N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák |
NZ726514A (en) | 2014-05-29 | 2019-01-25 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
CA2970924A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
JP6602875B2 (ja) | 2015-01-26 | 2019-11-06 | マクロジェニクス,インコーポレーテッド | Dr5結合ドメインを含む多価分子 |
FI3298033T4 (fi) | 2015-05-18 | 2023-09-22 | Tcr2 Therapeutics Inc | Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
HUE056201T2 (hu) | 2015-07-30 | 2022-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
US20170233472A1 (en) | 2016-02-17 | 2017-08-17 | Macrogenics, Inc. | ROR1-Binding Molecules, and Methods of Use Thereof |
KR102514317B1 (ko) | 2016-04-15 | 2023-03-27 | 마크로제닉스, 인크. | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 |
AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
AU2017341048A1 (en) | 2016-10-07 | 2019-05-23 | TCR2 Therapeutics Inc. | Compositions and methods for T-cell receptors reprogramming using fusion proteins |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
AR110424A1 (es) | 2016-12-23 | 2019-03-27 | Macrogenics Inc | Moléculas de unión a adam9 y métodos de uso de las mismas |
EP3589316A1 (en) * | 2017-02-28 | 2020-01-08 | Affimed GmbH | Combination of an anti-cd16a antibody with a cytokine |
DK3589655T3 (da) * | 2017-02-28 | 2022-11-28 | Affimed Gmbh | Tandem diabody til cd16a målrettet nk-celle optagelse |
MX2020006155A (es) | 2017-12-12 | 2020-08-13 | Macrogenics Inc | Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades. |
SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
CN113880952A (zh) | 2018-04-13 | 2022-01-04 | 艾菲默德有限责任公司 | 自然杀伤细胞接合抗体融合构建体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
DE10060140A1 (de) * | 2000-12-04 | 2002-06-06 | Vectron Therapeutics Ag Imt | Multimerer mehrfach-antigenbindender einzelkettiger Antikörper |
WO2003087163A1 (fr) * | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | Procede d'elaboration d'une banque scdb |
EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
-
2010
- 2010-02-25 ES ES10154751.1T patent/ES2582001T3/es active Active
- 2010-02-25 PL PL10154751.1T patent/PL2361936T3/pl unknown
- 2010-02-25 EP EP10154751.1A patent/EP2361936B1/en active Active
- 2010-02-25 PT PT101547511T patent/PT2361936T/pt unknown
- 2010-02-25 LT LTEP10154751.1T patent/LT2361936T/lt unknown
-
2011
- 2011-02-25 EP EP11156113.0A patent/EP2371866B1/en active Active
- 2011-02-25 PT PT11156113T patent/PT2371866T/pt unknown
- 2011-02-25 PL PL11156113T patent/PL2371866T3/pl unknown
- 2011-02-25 ES ES11156113T patent/ES2711377T3/es active Active
- 2011-02-25 SI SI201131675T patent/SI2371866T1/sl unknown
- 2011-02-25 RS RS20190201A patent/RS58352B1/sr unknown
- 2011-02-25 HU HUE11156113A patent/HUE041615T2/hu unknown
- 2011-02-25 DK DK11156113.0T patent/DK2371866T3/en active
- 2011-02-25 TR TR2019/02400T patent/TR201902400T4/tr unknown
- 2011-02-25 LT LTEP11156113.0T patent/LT2371866T/lt unknown
-
2019
- 2019-02-13 HR HRP20190288TT patent/HRP20190288T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
LT2361936T (lt) | 2016-09-12 |
PT2361936T (pt) | 2016-07-15 |
HUE041615T2 (hu) | 2019-05-28 |
PT2371866T (pt) | 2019-02-27 |
EP2371866A2 (en) | 2011-10-05 |
PL2371866T3 (pl) | 2019-05-31 |
HRP20190288T1 (hr) | 2019-04-05 |
PL2361936T3 (pl) | 2016-10-31 |
ES2582001T3 (es) | 2016-09-08 |
RS58352B1 (sr) | 2019-03-29 |
SI2371866T1 (sl) | 2019-04-30 |
EP2371866A3 (en) | 2013-06-26 |
EP2371866B1 (en) | 2018-11-21 |
EP2361936B1 (en) | 2016-04-20 |
LT2371866T (lt) | 2019-03-12 |
EP2361936A1 (en) | 2011-08-31 |
DK2371866T3 (en) | 2019-03-18 |
ES2711377T3 (es) | 2019-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201902400T4 (tr) | Multivalan antijen bağlama Fv molekülü. | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
EA201791393A3 (ru) | Антитела к erbb3 и их применение | |
AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
MX341921B (es) | Proteinas de union a antigeno. | |
AR077111A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
CA2808482C (en) | Methods for the generation of multispecific and multivalent antibodies | |
EA201790862A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
EA201390453A1 (ru) | Человеческие анти-тау антитела | |
RS52782B (en) | HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR |